recast-jats-buildd8e1462159jitcJ Immunother Cancer40425Journal for ImmunoTherapy of CancerJ Immunother Cancer2051-1426BMJ Publishing Group Ltds40425-018-0486-848610.1186/s40425-018-0486-830808427/jitc/7/1/56.atomCorrectionCorrection to: Treatment duration with immune-based therapies in Cancer: an enigmaBantiaShanta1aChoradiaNirmal2 Nitor Therapeutics 689, Highland Lakes Cove AL-35242 Birmingham USA Palo Alto Veterans Affairs Hospital 3801 Miranda Ave 94304 Palo Alto CA USA sbantia@nitortherapeutics.com 122019262201918112019181120192622019715617122018© The Author(s).2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Following publication of the original article [1], the authors reported an error in the typesetting of their article. The first section of the main text was mistakenly included in the abstract.

publisher-imprint-nameBioMed Centralvolume-issue-count1issue-article-count0issue-toc-levels0issue-pricelist-year2019issue-copyright-holderThe Author(s)issue-copyright-year2019article-contains-esmNoarticle-numbering-styleUnnumberedarticle-registration-date-year2018article-registration-date-month12article-registration-date-day17article-toc-levels0toc-levels0volume-typeRegularjournal-productArchiveJournalnumbering-styleUnnumberedarticle-grants-typeOpenChoicemetadata-grantOpenAccessabstract-grantOpenAccessbodypdf-grantOpenAccessbodyhtml-grantOpenAccessbibliography-grantOpenAccessesm-grantOpenAccessonline-firstfalsepdf-file-referenceBodyRef/PDF/40425_2018_Article_486.pdfpdf-typeTypesettarget-typeOnlinePDFissue-typeRegulararticle-typeErratumjournal-subject-primaryMedicine & Public Healthjournal-subject-secondaryOncologyjournal-subject-secondaryImmunologyjournal-subject-collectionMedicineopen-accesstrue

The original article can be found online at 10.1186/s40425-018-0465-0

Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:143

Doi: 10.1186/s40425-018-0465-0

Following publication of the original article [1], the authors reported an error in the typesetting of their article. The first section of the main text was mistakenly included in the abstract. This section begins with the sentence “Chemotherapy and immune-based therapies provide antitumor effects through completely different mechanisms” and ends with the following sentence:

“In exploring treatment duration with immune based therapies, we need to answer the following: (1) does indefinite treatment with immune based therapies exhaust the immune system counteracting its own mechanism of action leading to tumor progression and (2) how can clinical trials be designed to identify the optimal duration of immunebased therapy that prevents immune cell exhaustion but supports anti-tumor immunity.”

The published apologizes for any inconvenience caused by this error.

Reference Bantia and Choradia Journal for ImmunoTherapy of Cancer. 2018;6:143 doi:10.1186/s40425-018-0465-0